Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive

Status: Recruiting

Eligibility Criteria

Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed high grade serous epithelial ovarian cancer - stage III or IV disease and be appropriate to receive neoadjuvant chemotherapy (before surgery) - strenuous activity may be restricted but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work - women of childbearing potential (WCBP) must agree to use highly effective contraceptive method(s) while on MIRV and for at least 4 months after the last dose - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- previously treated with a systemic anti-cancer therapy - low-grade serous, endometrioid, clear cell, or mucinous cancer - women who have active or chronic corneal (eye) disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision - history of hepatitis B or C infection or human immunodeficiency virus (HIV) infection - women who are pregnant or breastfeeding - history of other cancer within 3 years prior - significant heart, lung, liver disease

Conditions & Interventions

Interventions:
Drug: mirvetuximab soravtansine (MIRV, IMGN853)
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Fallopian Tube, Ovarian Cancer, Primary Peritoneal Cancer

More Information

Description: The purpose of the study is to document the feasibility of undergoing surgery for cancer after receiving 3 cycles of neoadjuvant chemotherapy carboplatin and mirvetuximab soravtansine as first-line treatment in patients with advanced-stage ovarian cancer that are Folate Receptor alpha positive.
Study Contact: Britt Erickson - bkeric@umn.edu
Principal Investigator: Britt Erickson
Phase: PHASE2
IRB Number: STUDY00021464